AIM ImmunoTech

#10328

Rank

$6.94M

Marketcap

United States

Country

Leadership team

Mr. Thomas K. Equels Esq., J.D., M.S. (Exec. Vice Chairman, CEO & Pres)

Mr. Peter W. Rodino III, Esq., J.D. (COO, Exec. Director of Gov.al Relations, Gen. Counsel & Sec.)

Mr. Robert Dickey IV, M.B.A. (Chief Financial Officer)

Products/ Services

Biopharma, Biotechnology, Health Care

Headquarters

Orlando, Florida, United States

Established

1990

Company Registration

SEC CIK number: 0000946644

Traded as

AIM

Social Media

URL

https://www.aimimmuno.com

Overview

Location

Recognition and Award

References

Summary

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

History

AIM ImmunoTech was founded in 2000 with the goal of creating an immuno-inflammatory platform to research and develop products to treat immunologically related diseases. Over the years, the company has released new products and services and raised capital to expand its research and development activities.

Mission

Our mission is to develop treatments that help improve lives by targeting the immune system for better health outcomes.

Vision

Our vision is to be the leading provider of innovative and effective immunotherapeutic products and services to meet the needs of people suffering from immunologically related diseases.

Key Team

Jodie Pelz (Controller)

Dr. Ralph Christopher Cavalli Ph.D. (VP of QC & Manufacturing)

Dr. David R. Strayer M.D. (Chief Scientific Officer & Medical Director)

Ann Marie E. Coverly (Director of Admin. & HR and Deputy Investor Relations Coordinator)

Dr. Carol A. Smith (Chief Manufacturing Officer & Deputy Chief Scientific Officer)

Dr. Christopher McAleer Ph.D. (Scientific Officer)

Recognition and Awards

AIM ImmunoTech has won numerous awards for its research and development including the American Diabetes Association’s - National Diabetes Advocate of the Year award, the American Heart Association’s Outstanding Public Leadership Award, and the U.S. Small Business Administration’s Innovative Technology Award.